Novartis India Ltd — Important, 29-07-2026: Company Update

ChrysCapital has completed the acquisition of a controlling 70.68% stake in Novartis India Limited (NIL), previously a subsidiary of Novartis AG. This transaction brings NIL under dedicated private equity ownership, aiming to build a leading branded-generics platform for the Indian market. Dr. Vikas Gupta has been appointed MD and CEO, supported by new independent directors including Ramesh Ramadurai as Chairperson. NIL plans to adopt a new name and corporate identity, signaling a fresh strategic direction for its established portfolio of brands in key therapeutic areas like pain management, gynaecology, and neurosciences.